GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Total Assets
Latest total assets as of September 2025: ₹36.65 Billion INR
Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) holds total assets worth ₹36.65 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GlaxoSmithKline Pharmaceuticals Limited - Total Assets Trend (2005–2025)
This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GlaxoSmithKline Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
GlaxoSmithKline Pharmaceuticals Limited's total assets of ₹36.65 Billion consist of 83.0% current assets and 17.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 13.1% |
| Accounts Receivable | ₹3.61 Billion | 8.8% |
| Inventory | ₹4.82 Billion | 11.7% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹133.30 Million | 0.3% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GlaxoSmithKline Pharmaceuticals Limited's current assets represent 83.0% of total assets in 2025, an increase from 35.4% in 2005.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2025, up from 5.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 11.7% of total assets.
GlaxoSmithKline Pharmaceuticals Limited Competitors by Total Assets
Key competitors of GlaxoSmithKline Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
GlaxoSmithKline Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - GlaxoSmithKline Pharmaceuticals Limited generates 0.91x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, GlaxoSmithKline Pharmaceuticals Limited generates $ 22.58 in net profit.
GlaxoSmithKline Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.78 | 1.66 | 1.61 |
| Quick Ratio | 1.46 | 1.38 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹12.98 Billion | ₹ 12.01 Billion | ₹ 6.80 Billion |
GlaxoSmithKline Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between GlaxoSmithKline Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 26.78 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 15.5% |
| Total Assets | ₹41.08 Billion |
| Market Capitalization | $1.19 Billion USD |
Valuation Analysis
Below Book Valuation: The market values GlaxoSmithKline Pharmaceuticals Limited's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: GlaxoSmithKline Pharmaceuticals Limited's assets grew by 15.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)
The table below shows the annual total assets of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹41.08 Billion | +15.51% |
| 2024-03-31 | ₹35.57 Billion | +6.92% |
| 2023-03-31 | ₹33.27 Billion | -28.20% |
| 2022-03-31 | ₹46.33 Billion | +48.82% |
| 2021-03-31 | ₹31.13 Billion | -0.71% |
| 2020-03-31 | ₹31.36 Billion | -19.83% |
| 2019-03-31 | ₹39.11 Billion | -0.92% |
| 2018-03-31 | ₹39.47 Billion | +31.41% |
| 2017-03-31 | ₹30.04 Billion | -1.38% |
| 2016-03-31 | ₹30.46 Billion | -5.53% |
| 2015-03-31 | ₹32.24 Billion | +3.03% |
| 2014-03-31 | ₹31.30 Billion | +1.33% |
| 2013-03-31 | ₹30.88 Billion | +0.74% |
| 2012-03-31 | ₹30.66 Billion | +9.08% |
| 2011-03-31 | ₹28.10 Billion | +12.52% |
| 2010-03-31 | ₹24.98 Billion | +7.64% |
| 2009-03-31 | ₹23.21 Billion | +13.97% |
| 2008-03-31 | ₹20.36 Billion | +13.81% |
| 2007-03-31 | ₹17.89 Billion | +18.02% |
| 2006-03-31 | ₹15.16 Billion | +7.21% |
| 2005-03-31 | ₹14.14 Billion | -- |